EN | SE Contact us Careers

Meet us

Jan 18, 2021, SEB Annual Healthcare Seminar 2021

Jan 21, 2021, Redeye Fight Cancer 2021 > Link

Feb 16-18, 2021, BIO CEO & Investor Digital Conference, Online

Other news

BioInvent KOL Call: BI-1206 for Relapsed or Refractory NHL, 28 January at 11.30 am EST > Link

Presentation, DNB Nordic Healthcare Conference, December 15, 2020 > Presentation

Healthcare Direkt - Interview with Martin Welschof, CEO, October 28, 2020 > Interview

1907 FP Imonc


BioInvent’s primary goal is to develop next generation immuno-oncology drugs with a focus on improving therapeutic results in areas with significant unmet need.




BioInvent’s strategy is to leverage its expertise in immunology, cancer biology and antibody biology to develop cancer immunotherapies to improve the quality of life for cancer patients. This is accomplished through collaborations with pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. The goal is to create value for the Company’s shareholders based on successful drug development and subsequent revenue streams from existing and future commercial partners.


Our tools for successful drug development



In an automated process, we select optimal antibodies for new drug candidates from our own antibody library – one of the largest in the world.


Our unique and patented screening-platform has the advantage of simultaneously identifying disease-associated targets and antibodies that bind to them.


Our cGMP certified manufacturing site provides antibodies for in-house project development, as well as for external customers.


  • +/-
  • +/-
  • Opening price
  • Bid
  • Ask
  • High
  • Low
  • Volume
  • Turnover
  • Updated